An elevated PSA, which normalizes, does not exclude the presence of prostate cancer

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Elevated prostate-specific antigen (PSA) levels are a common indicator for prostate biopsy.
• A decrease in PSA levels before biopsy may be misinterpreted as a sign of reduced cancer risk.

Purpose of the Study:

• To investigate the incidence of prostate cancer in patients with an initially elevated PSA that normalizes before biopsy.
• To assess the diagnostic significance of PSA normalization in the context of prostate cancer detection.

Main Methods:

• Retrospective analysis of 160 patients with elevated referral PSA levels.
• Monitoring PSA levels to identify those that normalized to age-specific ranges before biopsy.
• Correlation of biopsy results with pre-biopsy PSA trends and digital rectal examination findings.

Main Results:

• Out of 160 patients, 21 (13%) showed a normalized PSA level before biopsy.
• Five of these 21 patients (24%) were diagnosed with prostate cancer post-biopsy.
• Two of the five cancer diagnoses occurred in patients with a clinically benign prostate examination.

Conclusions:

• PSA level normalization prior to prostate biopsy does not exclude the possibility of prostate cancer.
• Even with a normal PSA and a benign prostate exam, cancer may still be present.
• Clinical vigilance and biopsy are crucial regardless of PSA trend in high-risk patients.